NCCN Guidelines® Insights - Prostate Cancer, Version 3.2024 |
1.00 |
04/10/2024 - 12:00am to 04/10/2025 - 12:00am |
NCCN Guidelines® Insights - Mesothelioma: Pleural, Version 1.2024 |
1.00 |
03/10/2024 - 12:00am to 03/10/2025 - 12:00am |
NCCN Guidelines® Insights - Merkel Cell Carcinoma, Version 1.2024 |
1.00 |
01/10/2024 - 12:00am to 01/10/2025 - 12:00am |
NCCN Guidelines® Insights - Kidney Cancer, Version 2.2024 |
1.00 |
02/10/2024 - 12:00am to 02/10/2025 - 12:00am |
NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024 |
1.00 |
10/10/2023 - 12:00am to 10/10/2024 - 12:00am |
NCCN Guidelines® Insights - Distress Management, Version 2.2023 |
1.00 |
05/10/2023 - 12:00am to 05/10/2024 - 12:00am |
NCCN Guidelines® Insights - Cervical Cancer, Version 1.2024 |
1.00 |
12/10/2023 - 12:00am to 12/10/2024 - 12:00am |
NCCN Guidelines® Insights - Breast Cancer, Version 4.2023 |
1.00 |
06/10/2023 - 12:00am to 06/10/2024 - 12:00am |
NCCN Guidelines® Insights - Breast Cancer Screening and Diagnosis, Version 1.2023 |
1.00 |
09/10/2023 - 12:00am to 09/10/2024 - 12:00am |
NCCN Guidelines® Insights - Biliary Tract Cancers, Version 2.2023 |
1.00 |
07/10/2023 - 12:00am to 07/10/2024 - 12:00am |
NCCN Guidelines® Insights - B-Cell Lymphomas, Version 6.2023 |
1.00 |
11/10/2023 - 12:00am to 11/10/2024 - 12:00am |
NCCN 2024 Pharmacy Updates: A Webinar Series |
|
01/29/2024 - 12:00am to 12/31/2024 - 12:00am |
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Multigene and Biomarker Testing in Breast Cancer |
1.00 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |